Author

Véronique Gigoux

Centre de Recherches en Cancérologie de ToulouseORCID 0000-0003-1408-5335Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Corinne BousquetiD· 2 shared Ahmed Gamal Ali AbdelhamidiD· 1 shared Chloe Bazile· 1 shared Fabien GavaiD· 1 shared Flavien RaynaliD· 1 shared G. BalloniD· 1 shared Julian CarreyiD· 1 shared Julie Bordenave· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Corinne BousquetORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 8, 2026

Origin of Fe ions in ROS production induced in magnetic hyperthermia anti-cancer nanotherapy: release from iron oxide nanoparticles or not?

Justine Journaux, Megi Bejko, Pascal Clerc…·Véronique Gigoux

The paper investigates whether Fe ions released from iron oxide nanoparticles are necessary for ROS production in magnetic hyperthermia anti-cancer therapy, finding that ROS production and cell death can occur without Fe3+ release.

DOI 10.64898/2026.07.06.736751

experimental assaycancer & tumor microenvironment

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 16, 2025

Targeting human M2 macrophages with antibodies in optimized 3D tumor spheroids

Chloe Bazile, Fabien Gava, Flavien Raynal…·Mary Poupot

This study develops an in vitro 3D tumor spheroid model to target pro-tumoral macrophages with antibodies, showing effective killing even in spheroid centers.

DOI 10.1101/2025.09.16.676563

humanexperimental assay

𝕏 PostBluesky